Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863967 | 0.81 | TRPV1 (0.46) | TRPV1RORCKMT2A | |
| SCHEMBL4256775 | 0.81 | LMNA (0.61) | TRPV1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4869497 | 0.78 | TRPV1 (0.45) | TRPV1RORC | |
| SCHEMBL782123 | 0.72 | MAPT (0.44) | TRPV1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1253664 | 0.72 | TRPV1 (0.67) | TRPV1RORC | |
| SCHEMBL1250889 | 0.69 | TRPV1 (0.68) | TRPV1RORC | |
| SCHEMBL3815501 | 0.68 | TRPV1 (0.54) | TRPV1LMNARORCCYP2C19 | |
| SCHEMBL4263851 | 0.66 | GRM5 (0.64) | LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15758083 | 0.66 | ASPH (0.55) | — | |
| SCHEMBL31693360 | 0.66 | ASPH (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | TRPV1 112/4885LMNA 3472/4885RORC 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.